Vivos Therapeutics Inc Cash Flow-to-Debt Ratio
Vivos Therapeutics Inc cash flow-to-debt ratio. Vivos Therapeutics Inc (VVOS) has a Cash Flow-to-Debt Ratio of -0.11x as of June 2026, meaning its operating cash flow of $-3.15 Million could theoretically repay 0% of its total liabilities ($28.13 Million) in one year. See Vivos Therapeutics Inc financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Vivos Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of Vivos Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for Vivos Therapeutics Inc across 8 annual periods. Also explore VVOS year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Vivos Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Vivos Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Vivos Therapeutics Inc. For the full cash flow conversion analysis, see Vivos Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.57x | $-15.26 Million | $26.70 Million | ▲ +67.0% |
| 2024 | -1.73x | $-12.69 Million | $7.33 Million | ▼ -49.6% |
| 2023 | -1.16x | $-11.95 Million | $10.32 Million | ▲ +47.3% |
| 2022 | -2.20x | $-19.59 Million | $8.92 Million | ▼ -13.7% |
| 2021 | -1.93x | $-15.73 Million | $8.15 Million | ▼ -185.9% |
| 2020 | -0.68x | $-5.68 Million | $8.41 Million | ▼ -32.7% |
| 2019 | -0.51x | $-5.34 Million | $10.49 Million | ▲ +67.7% |
| 2018 | -1.57x | $-5.31 Million | $3.38 Million | — |